Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
BRAINSTORM CELL THERAPEUTICS INC. See All Filings	D	2019-08-09 17:09:04 UTC
Amount To Be Raised Indefinite Associated Brokers / Dealers N/A CIK Number 0001137883 Filed Document 0001144204-19-038938 Exclusions or Exemptions 506b Accepted Date 2019-08-09 17:09:04 UTC Type of Offering D Industry Biotechnology Principal Place of Business NEW YORK Revenue or Assets Decline to Disclose Type of Security Option To Acquire
BRAINSTORM CELL THERAPEUTICS INC. See All Filings	D	2018-06-20 06:03:19 UTC
Amount To Be Raised Indefinite Associated Brokers / Dealers N/A CIK Number 0001137883 Filed Document 0001144204-18-034895 Exclusions or Exemptions 506b Accepted Date 2018-06-20 06:03:19 UTC Type of Offering D Industry Biotechnology Principal Place of Business NEW YORK Revenue or Assets Decline to Disclose Type of Security Option To Acquire
BRAINSTORM CELL THERAPEUTICS INC. See All Filings	D	2015-01-16 00:00:00 UTC
Amount To Be Raised Indefinite Associated Brokers / Dealers Maxim Partners LLC CIK Number 0001137883 Filed Document 0001144204-15-002944 Exclusions or Exemptions 506b Accepted Date 2015-01-16 00:00:00 UTC Type of Offering D Industry Biotechnology Principal Place of Business NEW JERSEY Revenue or Assets Decline to Disclose Type of Security Option To Acquire
BRAINSTORM CELL THERAPEUTICS INC. See All Filings	D	2014-06-30 00:00:00 UTC
Amount To Be Raised $10,500,000 Associated Brokers / Dealers Maxim Group LLC CIK Number 0001137883 Filed Document 0001144204-14-040621 Exclusions or Exemptions 506b Accepted Date 2014-06-30 00:00:00 UTC Type of Offering D Industry Biotechnology Principal Place of Business NEW YORK Revenue or Assets Decline to Disclose Type of Security Equity
BRAINSTORM CELL THERAPEUTICS INC. See All Filings	D	2014-05-09 00:00:00 UTC
Amount To Be Raised $2,470,590 Associated Brokers / Dealers N/A CIK Number 0001137883 Filed Document 0001144204-14-028971 Exclusions or Exemptions 506b Accepted Date 2014-05-09 00:00:00 UTC Type of Offering D Industry Biotechnology Principal Place of Business NEW YORK Revenue or Assets Decline to Disclose Type of Security Equity